News | Page 4 of 5 | Blueprint Genetics

Blueprint Genetics / News / Page 4

News

Media contact & Media kit

Blueprint Genetics is one of the most promising growth companies in Finland

Feb 05, 16

Blueprint Genetics has been chosen as one of the top 20 most promising growth companies in 2016 by Talouselämä. Talouselämä, a Finnish weekly financial and business magazine, has chosen the most promising start-up companies in Finland for the fifth year in a row. The jury judged the growth and internationalization possibilities…

Blueprint Genetics becomes the first laboratory to receive ISO 15189 accreditation for a NGS pipeline from sample arrival to clinical interpretation

Feb 02, 16

Blueprint Genetics is now an ISO 15189 standard accredited No. T292 laboratory. Accreditation is a procedure to recognize an organization’s competence to carry out specific tasks based on internationally agreed criteria. The quality management system at Blueprint Genetics complies with the international ISO 15189 standard, which specifies the quality requirements for medical…

Relevance of Truncating Titin Mutations in Dilated Cardiomyopathy

Jan 28, 16

As a continuation to Blueprint Genetics recent collaborative studies on genetics of dilated cardiomyopathy (DCM) (Eur Heart J 2015 and PlosOne 2015), we performed meta-analysis of truncating titin variants in DCM. Others and we have previously estimated TTN truncating variants (TTNtv) – nonsense, frameshift and consensus splice site, to be responsible for…

Prevalence of Titin Truncating Variants in General Population

Jan 11, 16

As a continuation to Blueprint Genetics recent collaborative study on genetics of dilated cardiomyopathy (Eur Heart J 2015), we were enthusiastic to further evaluate variation of titin gene in large reference populations. This is an important step towards a better understanding of the titin truncations in cardiomyopathies. Earlier studies have…

2015 was great for genetic diagnostics but 2016 will be even better

Dec 18, 15

As the holiday season is approaching, we want to thank all of our customers, partners and collaborators for the great year. During 2015 we expanded into new territories and had the privilege to learn from and work with physicians and researchers from all over the world. We are very pleased…

“Diagnostics startup Blueprint Genetics puts expansion to the test” / Tekes

Nov 15, 15

“After establishing an office in the USA, business is set to grow tenfold for this genetic testing company in the near future. The road to success for startups is one that is typically paved with various twists and turns. Whilst a company may start out with an original idea, in…

Blueprint Genetics receives California CLIA State License and launches diagnostics sales in California.

Nov 03, 15

We are thrilled to start providing customers in California with our world-class genetic testing and diagnostics! Blueprint Genetics is a CLIA certified laboratory for high complexity testing (#99D2092375) approved by US authorities (Centers of Medicare & Medicaid Services – Clinical Laboratory Improvement Amendment Survey and…

Looking ahead—expanding to cover all inherited disorders

Oct 08, 15

During the last couple of years, we’ve focused our efforts on developing our cardiovascular diagnostics. This emphasis has helped establish our place as one of the leading global providers of cardiovascular genetic diagnostics. As of March 2016, we are taking the company to a next level by radically expanding our…

Frontiers in molecular genetic diagnostics of pulmonary arterial hypertension (PAH)

Sep 02, 15

Genetic basis of pulmonary arterial hypertension (PAH) is well recognised but still rarely utilized in diagnostics setting. Diagnostic yield of comprehensive multi-gene panels in PAH is relatively unknown as current knowledge is gathered from studies evaluating only one gene at a time in a heterogenous patient populations. Finnish PAH…

Investigating the genetic landscape of DCM in the Finnish population

Aug 27, 15

To explore the underlying genetic defects of dilated cardiomyopathy (DCM) we applied OS-Seq technology as a novel comprehensive diagnostic tool. Despite our increasing understanding of the genetics of DCM the genetic basis of the disease is still poorly understood. We were able to identify pathogenic variants in 47.6% of the…

Come meet us this spring at HRS, AEPC and ESHG

Apr 13, 15

We are continuously participating in events around the world. Come meet us at the following conferences during spring and summer 2015. More details about our participation, booth number etc. are also found on our Facebook page. HRS – Heart Rhythm 2015 36th Annual Scientific…

Exceptional findings with OS-Seq in an arrhythmia patient

Apr 09, 15

Sequencing of channelopathy genes with the BpG Arrhythmia Panel revealed a de novo mutation in the CACNA1C gene in an adolescent with ventricular fibrillation but normal development, consequently not only expanding the phenotype of Timothy Syndrome Type 2 but also demonstrating the power of large gene panels. The standard has been to select specific gene tests for patients with established…

Meet Sampo, our new NextSeq 500 Desktop Sequencer

Mar 27, 15

We have a tradition of naming our sequencing machines after famous robots. Our latest system is called Sampo. In the Finnish national epoch compiled by Elias Lönnrot, Kalevala, Sampo is described as a refiner engine that brought prosperity to its owner. Pretty witty, huh? Currently, we are using Illumina’s MiSeqs…

Check out our latest video and find out how we are revolutionizing genetic testing

Mar 25, 15

One of the 20 most promising start-ups in Finland 2015

Mar 25, 15

Finnish business magazine Talouselämä has released its take on the 20 most promising start-ups in Finland. Blueprint Genetics is one of the companies! Read more… (Order Talouselämä or try ’Summa’ one month for free to read the full story.)…

Big news for Blueprint Genetics at the 2015 Annual Clinical Genetics Meeting

Mar 24, 15

The 2015 Annual Clinical Genetics Meeting (ACMG) marks an important milestone for us at Blueprint Genetics, one of the leading laboratories in cardiovascular genetics. At this meeting we’re excited to announce our new and improved service model, plus our upcoming sales launch in the US. We’re opening new facilities…

Blueprint Genetics – Ready for 2015!

Dec 18, 14

Blueprint Genetics thanks all hospitals and clinics, which have collaborated with us and utilized our diagnostic services during year 2014 and wishes all of you a Happy New Year 2015! During 2014 our customer base has exceeded over 90 clinics and hospitals in 31 countries. From these hospitals we have…

Blueprint Genetics is launching new products neurological diseases

Nov 03, 14

Blueprint Genetics launches new genetic diagnostic tests for Becker and Duchenne muscular dystrophies and an updated panel for Emery-Dreifuss muscular dystrophy with the addition of titin (TTN) gene. In line with our other diagnostic panels, we target the sequencing to all protein coding exons, exon-intron boundaries and other regions with…

Blueprint Genetics Announces $3.9 Million in Funding, Leading to US Expansion

Aug 29, 14

Helsinki, Finland – August 29, 2014 – Blueprint Genetics is glad to announce that Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, have joined the existing investors of the company. Previously, the company has been financed by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation. The funding for Blueprint Genetics now totals…

Blueprint Genetics Announces $3.9 Million in Funding, Leading to US Expansion

Aug 29, 14

Blueprint Genetics is glad to announce that Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, have joined the existing investors of the company. Previously, the company has been financed by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation. The funding for Blueprint Genetics now totals $3.9 million, allowing the company to accelerate…

Media kit

Subscribe to our press releases